Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical ...

AstraZeneca has received approval from the FDA for its BTK inhibitor, Calquence (acalabrutinib), for first-line use in MCL.

If the results from the clinical development plans are positive, it may well reflect a paradigm shift for clinical care.

Japanese drugmaker Sumitomo Pharma Company has concluded a co-promotion collaboration partner agreement with US healthcare ...

Ash Shehata from KPMG discusses how investors are feeling about the pharma and life sciences industry heading into 2025.